Curriculum Vitae

Nigel Pearson Buller BSc. MB. BS. FRCP.

37 Fentiman Road,
London, SW8 1LD.
Tel: 020 7735 1775
nigelbuller@aol.com

Edwards v. Aortic Innovations
U.S. Patent 11,497,634
Edwards Ex. 1004

Date of birth: 5th July 1955.

Nationality: British.

Qualifications:

1977 BSc.
1st Class Honours
University of London,

1980 MB BS.
St Thomas' Hospital Medical School,
University of London.

1983 MRCP UK.

1996 FRCP

GMC Registration No: 2647919

MDU Membership No: 150200X

Membership of Societies and Associations:

British Cardiac Society.
British Cardiovascular Intervention Society.
European Society of Cardiology
Royal College of Physicians.

Previous Appointments:

1-2-95 until 2015	Consultant Cardiologist, BMI The Edgbaston Hospital, Edgbaston, Birmingham B15 2QQ.
1-2-95 until 2010	Honorary Senior Lecturer, Department of Cardiovascular Medicine, University of Birmingham.
1-2-95 to 11-1-08	Consultant Cardiologist and Head of Interventional Cardiology, University Hospital Birmingham NHS Trust Birmingham B15 2TH
1-3-91 to 31-1-95	Senior Lecturer, Department of Cardiac Medicine, National Heart & Lung Institute. London SW3 6LY.
1-3-91 to 31-1-95	Honorary Consultant Cardiologist, Royal Brompton Hospital, London SW3 6NP.
1-6-90 to 31-2-91	Cardiology Senior Registrar Harefield Hospital, Middlesex.
1-5-89 to 31-5-90	Cardiology Senior Registrar The Royal Free Hospital, London.
1-4-87 to 31-3-89	Cardiology Registrar The National Heart Hospital, London.
5-1-87 to 31-3-87	Lecturer, Department of Cardiac Medicine The Cardiothoracic Institute, London.
1-3-86 to 31-3-87	British Heart Foundation Junior Research Fellow The Cardiothoracic Institute, London.
1-3-86 to 31-3-87	Honorary Cardiology Registrar The National Heart Hospital, London.

1-6-85 to 31-2-86	Project Chairman Cardiovascular Development Smith Kline & French Research Limited, Philadelphia PA. USA.
1-11-84 to 31-2-86	Research Physician Smith Kline & French Research Limited, Philadelphia PA. USA.
1-11-83 to 31-10-84	General Medical Registrar St Thomas' Hospital Registrar Rotation. St Richard's Hospital, Chichester.
16-2-83 to 16-8-83	SHO, Department of Nephrology St Thomas' Hospital, London.
1-9-82 to 15-2-83	SHO, Department of Neurology Guy's Hospital, London.
1-2-82 to 31-7-82	SHO, Department of Cardiology The Middlesex Hospital, London.
1-8-81 to 31-1-82	SHO, Intensive Therapy Unit St Thomas' Hospital, London.
1-8 81 to 31-1-82	SHO, Phipps Respiratory Unit South Western Hospital, London
1-2-81 to 31-7-81	HO, Department of Surgery West Suffolk Hospital, Bury St Edmonds.
1-8-80 to 31-1-81	HO, Department of Gastroenterology St Thomas' Hospital, London.

PUBLICATIONS:

Books:

The contractile behaviour of mammalian skeletal muscle.
Buller AJ, Buller NP.
Carolina Biology Readers 1980.

Left ventricular function in stunned and hibernating myocardium.
Editors: Buller NP, Henderson AH, Krayenbuhl HP.
Excerpta Medica 1992.

Current Diagnosis and Treatment
Editor-in-chief: Pounder R, Hamilton M.
Editor cardiology section: Buller NP.
Churchill Livingstone 1995.

Journals:

Interventional Cardiology Monitor.
Editors: King III SB, Topol EJ, Nobuyoshi M, Buller NP, Serruys PW.
Current Medical Literature.

Seminars in Interventional Cardiology.
Member of the International Advisory Board.
WB Saunders Company Ltd.

Scientific Papers, Articles and Book Chapters:

1. Buller NP Stephens JA
Changes in the probability of firing of human motor units following stimulation of muscle receptors.
J. Physiol 1977; 271: 1-2P

2. Stephens JA, Garnett R, Buller NP.
Reversal of recruitment order of single motor units produced by cutaneous stimulation during voluntary muscle contraction in man.
Nature 1978;272:362-364.

3. Buller NP, Garnett R, Stephens JA.
The use of skin stimulation to produce reversal of motor unit recruitment order during voluntary muscle contraction in man.
J. Physiol. 1978; 277: 1-2P

4. Buller NP, Garnett R, Stephens JA.
The reflex response of single motor units in human hand muscles following muscle afferent stimulation.
J. Physiol 1980;303:337-349.

5. Scott SC, Locke-Haydon J, Pready NS, Buller NP, Cregeen RJ.
Ibopamine (SK&F 100168) pharmacokinetics in relation to the timing of meals.
Br. J. Clin. Pharmac. 1987;23:585-587.

6. Buller NP.
Non-invasive measurement of cardiac output.
Lancet 1987;i:215.

7. Buller NP.
Exercise testing in chronic heart failure.
Topics in Circulation. 1987;2:2-4.

8. Lipkin DP, Buller NP, Frenneaux M, Ludgate L, Lowe T, Webb SC,
Krikler DM.
Randomized crossover trial of rate responsive Activitrax and conventional fixed rate ventricular pacing.
Br. Heart J. 1987;58:613-616.

9. Buller NP.
Heart Failure.
Cardiovascular Update.1987;8:3-10.

10. Buller NP, Poole-Wilson PA.
"Extrapolated maximal oxygen consumption"; a new method for the objective analysis of respiratory gas exchange during exercise.
Br. Heart J. 1988;59:212-217.

11. Poole-Wilson PA, Buller NP.
Cause of symptoms in chronic congestive heart failure; implications for treatment.
Am. J. Cardiol. 1988; 62; 31-34.

12. Urban P, Buller NP, Fox K, Shapiro L, Bayliss J, Rickards AF.
Lack of effect of warfarin on the restenosis rate and clinical outcome after balloon coronary angioplasty.
Br. Heart J. 1988: 60; 6; 485-488.

13. Poole-Wilson PA, Buller NP, Lipkin DP.
Regional blood flow, muscle strength and skeletal muscle histology in severe congestive heart failure.
Am J Cardiol. 1988;62:49E-52E.

14. Buller NP, Poole-Wilson PA.
Mechanism of the increased ventilatory response to exercise in patients with chronic heart failure.
Br. Heart J. 1990: 63; 281-283.

15. Buller NP, Jones D, Poole-Wilson PA.
Direct measurement of skeletal muscle fatigue in patients with chronic heart failure.
Br. Heart J. 1991;65:20-24.

16. Hackett D, Andreotti F, Haider A, Brunelli C, Shahi M, Fussell A,
Buller NP, Foale R, Lipkin D, Caponetto S, Davies G, Maseri A.
Effectiveness and safety of a single bolus injection of tissue-type plasminogen activator in acute myocardial infarction.
Am. J. Cardiol. 1992:69:1393-1398.

17. Gibbs JSR, Slade AKB, Blake J Nordrehaug JE, Rickards AF, Buller NP Sigwart U.
Femoral arterial haemostasis using a collagen plug after coronary artery stent implantation.
J. Interventional Cardiol. 1992;5:85-88.

18. Priestley KA, Campbell C, Valentine CB, Denison DM, Buller NP.
Are patient consent forms for research protocols easy to read?
Br Med J. 1992;305:1263-1264.

19. Poole-Wilson PA, Buller NP, Lindsay DC.
Blood flow in skeletal muscle in patients with heart failure.
Chest. 1992; 101:330S-332S.

20. Priestley K, Buller NP.
Percutaneous coronary intervention for diffuse coronary artery disease.
J Intervent Cardiol. 1993;6:25-29.

21. Nordrehaug JE, Priestley K, Chronos N, Buller NP, Sigwart U.
Implantiation of half Palmaz-Schatz stents in short aorto-ostial lesions of saphenous vein grafts.
Cathet Cardiovasc Diagn. 1993;29:141-143.

22. Nordrehaug JE, Priestley K, Rickards AF, Buller NP, Sigwart U.
Simultaneous implantation of two Palmaz-Schatz stents mounted on a long angioplasty balloon.
J. Interv. Cardiol. 1993; 3: 223-225.

23. Henein MY, Priestley K, Davarashvili T, Buller NP, Gibson DG.
Early changes in left ventricular subendocardial function after successful coronary angioplasty
Br Heart J. 1993;69:501-507.

24. Stewart JT, Denne L, Bowker TJ, Mulcahy DA, Williams MG, Buller NP, Sigwart U, Rickards AF.
Percutaneous transluminal coronary angioplasty in chronic coronary artery occlusion.
J Am Coll Cardiol. 1993;21:1371-1376.

25. Chronos N, Goodall AH, Wilson DJ, Sigwart U, Buller NP.
Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology.
Circulation 1993;88:2035-2044.

26. Chronos N, Buller N.
Thrombotic considerations in the choice of an angiographic contrast medium.
Rad Magazine 1993. 19.

27. Gibbs SR, Sigwart U, Buller NP.
Temporary stent as a bale-out device during percutaneous transluminal coronary angioplasty: Preliminary clinical experience.
Br Heart J. 1994;71:372-377.

28. Karsch KR. et al for the Coinvestigators of the European Coronary Excimer Laser Angioplasty Registry.
Clinical results of coronary eximer laser angioplasty: report from the European Coronary Excimer Laser Angioplasty Registry.
Eur Heart J. 1994; 15:89-96.

29. Gibbs JSR, Murdoch LJ, Goldstraw P, Buller NP.
Removal of a dental post from the bronchus using interventional cardiovascular techniques.
Thorax 1994;49:526-527.

30. Serruys PW., et al. for the Benestent Study Group.
A comparison of balloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease.
New Eng J Med. 1994;331: 489-495.

31. Nordrehaug JE, Priestley K, Chronos NAF, Rickards AF, Buller NP, Sigwart U.
Self-expanding stents for the management of aorto-ostial stenoses in native coronary arteries and bypass grafts..
Br Heart J. 1994; 72:285-288.

32. Buller NP, Serruys P.
Stent trials update: The Benestent Trial.
Interventional Cardiol Newsletter. 1994:2:35-38.

33. Chronos N, Stables R, Gibbs S, Nordrehaug JE, Sigwart U, Buller NP.
Temporary stenting as a bridge to surgery.
J Int Cardiol. 1994:7;327-330.

34. Chronos NAF, Wilson DJ, Janes SL, Hutton RA, Buller NP, Goodall AH.
Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of alpha granules or lysosomes from, human platelets.
Clin Science 1994:87;575-580.

35. Stables RH, Patel DJ, Buller NP.
Advances in the treatment of unstable angina.
Br. J. Cardiol 1994; 1:65-69.

36. Nordrehaug JE, Priestley K, Chronos NAF, Rickards AF, Buller NP, Sigwart U.
Self-expanding stents for emergency treatment of acute vessel closure following coronary angioplasty: immediate and long-term results.
J Interv Cardiol. 1994:7;161-4.

37. Stables R, Buller N, Denison D.
Reward-winning data entry.
Br J Healthcare Computing and Information Management. 1995:12;28-29.

38. Thorne S, Buller N.
Angina Pectoris.
Handbook of Current Diagnosis and treatment. 1995; Current Medicine Inc.

39. Thorne S, Buller N.
Unstable angina.
Handbook of Current Diagnosis and treatment. 1995; Current Medicine Inc.

40. Stables RH, Buller NP.
A computer database system for the cardiac catheterisation laboratory: Improving clinical data collection with an advanced graphical user interface.
Focus on outcome analysis. 1995:3;7-12.

41. CABRI Trial Participants.
First-year results of CABRI (Coronary angioplasty versus bypass revascularisation investigation).
Lancet. 1995; 346: 1179-1184

42. Priestley KA, Clague JE, Buller NP, Sigwart U.
First clinical experience with a new flexible low profile metallic stent and delivery system.
Euro. Heart J. 1996; 17: 438-444.

43. Brady AJB, Buller NP.
Coronary angioplasty and myocardial ischaemia.
Care of the Critically Ill. 1996; 12: 83-86.

44. Keane D, et al. on behalf of the BENESTENT Investigators.
Clinical and angiographic outcome of elective stent implantation in small coronary vessels: an analysis of the BENESTENT trial. 34. CABRI Trial Participents.
Seminars in Interventional Cardiol. 1996; 1:255-262.

45. Townend JN, Buller NP.
Coronary angioplasty plus stent in LAD disease.
Lancet. 1996; 347: 689.

46. Buller N (and others).
Management of stable angina.
Effective Health Care. 1997; 3: 1-8.

47. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators.
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
N. Engl. J. Med. 1998; 338: 1498-505.

48. Heijer PD, Vermeer F, Ambrosioni E, et al on behalf of the InTime Investigators.
Evaluation of a weight-adjusted single-bolus Plasminogen activator in patients with myocardial infarction. A double-blind, randomised angiographic trial of Lanoteplase versus Alteplase.
Circulation. 1998; 98: 2117-2125.

49. Kurbaan AS, Bowker TJ, Ilsley CDJ, Rickards AF (on behalf of the CABRI investigators)
The impact of post angioplasty restenosis on comparisons of outcome between angioplasty and bypass grafting.
Am. J. Cardiol. 1998; 82: 272-276.

50. Serruys PW, Unger F, et al. On behalf of the ARTS study-group.
The ARTS Study (Arterial revascularization therapies study).
Seminars in Interventional Cardiology. 1999; 4: 209-219.

51. Eccleshall SC, Jordan PJ, Buller NP, Townend JN.
In-vitro validation of the luminal measurement of a novel catheter-based moulding technique.
Heart. 1999; 81: 206-211.

52. Serruys PW, et al on behalf of the ARTS study group.
The ARTS (Arterial Revascularisation Therapies Study): Background, goals and methods.
Int. J. Cardiovasc. Interventions 1999; 2: 41-50.

53. MRC/BHF Heart Protection Study Collaborative Group.
MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.
Euro. Heart J. 1999; 20: 725-741

54. Serruys PW, Unger F, Sousa E, Jatene A, Bonnier J, Schonberger JM, Buller NP, Bonser R, van den Brand MJB, Herwerden LA, Morel MM, van Hout BA, for the ARTS study group.
Comparison of Coronary-Artery Bypass Surgery and Stenting for the treatment of Multivessel Disease.
N. Engl. J. Med. 2001; 344: 1117- 1124.

55. Abizaid A, et al on behalf of the ARTS Investigators.
Clinical and Economic Impact of Diabetes Mellitus on Percutaneous and Surgical Treatment of Multivessel Coronary Disease Patients.
Circulation. 2001; 104: 533-538.

56. Eccleshall SC, Jones H, Lichfield M, Jordan PJ, Buller NP, Townend JN.
Clinical and angiographic results of the elective deployement of the 7-cell NIR stent in coronary arteries <2.75 mm in diameter
Cath and Cardiovascular Intervention. 2001;54: 174-179

57. Costa MA, et al on behalf of ARTS study group.
Incidence, Predictors, and Significance of Abnormal Cardiac Enzyme Rise in Patients Treated With Bypass Surgery in the Arterial Revascularisation Therapies Study (ARTS).
Circulation. 2001: 104: 2689-2693..

58. Heart Protection Study Collaborators Group.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individials: a randomised placebo-controlled trial. Heart protection study collaborative group.
Lancet. 2002; 360: 7-22.

59. Heart Protection Study Collaborators Group
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high risk individuals: a randomised placebo-controlled trial. Heart protection study collaborative group.
Lancet. 2002; 360: 23-36.

60. Buller NP, Gillen D, Casiano R, Doyle J, Wilson K. A pharmacoeconomic evaluation of the myocardial ischaemia reduction with aggressive cholesterol lowering (MIRACL) study in the United Kingdom.
Pharmacoeconomics. 2003; 21: 25-32.

61. Legrand VMG, et al on behalf of the Arterial Revascularization Therapy Study (ARTS) Investigators.
Three-Year Outcome After Coronary Stenting Versus Bypass Surgery for the Treatment of Multivessel Disease.
Circulation. 2004; 109: 1114-1120.

62. Heart Protection Study Collaborative Group.
MRC/BHF Heart Protection study of cholesterol-lowering with Simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
Lancet 2003; 361: 2005-2016.

63. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebro vascular disease or other high-risk conditions.
Lancet 2004: 363: 757-767.

64. Bowater SE, Doshi SN, Buller NP. Subacute stent thrombosis successfully treated with thrombolysis and glycoprotein IIb/IIIa inhibition.

Heart 2005; 91: 488.

65. Aoki J, Ong AT, Hoye A Van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, Schonberger JP, Buller N, Bonser R, Lindeboom W, Unger F, Serruys PW.
Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial.
Eur Heart J. 2005;26:1488-93

66. Heart Protection Study Collaborative Group.
The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].
BMC Med. 2005 Mar 16;3(1):6.

67 Gruberg L, et al on behalf of the Arterial Revascularization Therapies Study Investigators.
Impact of Body Mass Index on the Outcome of Patients With Multivessel Disease Randomized to Either Coronary Artery Bypass Grafting or Stenting in the ARTS Trial: The Obesity Paradox II?
Am. J. Cardiol. 2005; 95: 439-444.

68. Serruys PW, Ong ATL, Van Herwerden LA, Sousa JE, Jatene J, Bonnier JJRM, Schonberger JPMA, Buller NP, Bonser RS, Disco C, Backx B, Hugenholtz PG, Firth BG, Unger F. Five year outcomes after coronary stenting verses bypass surgery for the treatment of multivessel disease: The final analysis of the ARTS randomised trial.
JACC 2005;46:575-581.

69. Heart Protection Study Collaborative Group. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: a randomised trial in 20,536 high risk individuals.
Lancet 2005;365:1779-1785

70. Newman MH, Starkey I, Buller NP, Seabra-Gomes R, Kirby S, Hettiarachchi J, Cumberland D, Hillis WS. The effects of Sumatriptan and Eletriptan on the epicardial coronary arteries of patients undergoing percutaneous revascularisation for single-vessel coronary artery disease.
Eur. J. Pharmacol 2005;61:733-742

71. Heart Protection Study Collaborative Group. Lifetime cost-effectiveness of simvastatin in a range of risk groups and age groups derived from randomised trial of 20,536 people individuals.
BMJ 2006;333:1145-1148.

72. Routlage HC, Ludman PF, Doshi SN, Townend JN, Buller NP.
How safe is femoral access? Insights from an audit of contemporary practice.
British J. Cardiology; 2007; 14:165-168.

73. Mistry S, Ives N, Harding J, Fitzpatrick-Ellis K, Lipkin G, Kalra PA, et al. Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far.
J Hum Hypertens. 2007;21:511-5.

74. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R.
SLCO1B1 variants and statin-induced myopathy--a genomewide study.
N Engl J Med. 2008;359(8):789-99.

75. Heart Protection Study Collaborative Group, Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, Collins R.
N-terminal Pro-B-type natriuretic peptide, vascular disease risk and cholesterol reduction amoung 20,536 patients in the MRC/BHF heart protection study.
J. Am. Coll. Cardiol. 2007; 49: 311-319.

76. Osman F, Buller N, Steeds R. Use of intra-arterial papaverine for severe arterial spasm during radial cardiac catheterization.
J Invasive Cardiol. 2008;10:551-2.

77. Heart Protection Study Collaborative Group.
Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels.
Circ. Cardiovasc. Qual. Outcomes. 2009; 2:65-72.

78. The ASTRAL Investigators. Revascularization versus Medical Therapy for Renal-Artery Stenosis.
N Engl J Med. 2009;361:1953-62

79. Chue CD, Routledge HC, Ludman PF, Townend JN, Epstein ACR, Buller NP, Doshi SN.
3-Year Follow-Up of 100 Consecutive Coronary Bifurcation Lesions Treated with Taxus Stents and the Crush Technique.
Cath Cardiovasc Interv. 2010; 75: 605-613

80. Study of the Effectiveness of Aditional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R.
Intensive lowering of LDL cholesterol with 80 mg Versus 20 mg Simvastatin Daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
Lancet 2010; 376: 1658-68

81. Study of the Effectiveness of Aditional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, , Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Sleight P, Peto R, Collins R.
Effects of homocysteine-lowering with folic acid plus vitamin B12 versus placebo on mortality and major morbidity in myocardial infarction survivors: a randomised trial.
JAMA 2010; 303: 2486-94

82. Heart Protection Study Collaborative Group, Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, Collins R.Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
Lancet. 2011 Dec 10;378(9808):2013-20.

Abstracts:

Buller NP, Ismail HM, Rangatunga KW.
Recording of isometric contractions of human biceps brachii muscle.
J. Physiol. 1978;277:11-12P.

Scott SC, Buller NP, Murkitt GS, Cregeen RJ.
Pharmacokinetic interaction between Ibopamine and food.
Proceedings 10th World Congress of Cardiology. Washington 1986.

Scott SC, Sheppard TA, Clancy A, Buller NP, Cregeen RJ.
Ibopamine and digoxin; an interaction study.
Proceedings of the 3rd World Congress on Clinical Pharmacology and Therapeutics.
Stockholm. 1986.

Buller NP, Poole-Wilson PA.
An objective assessment of maximal exercise capacity from a submaximal exercise test in patients with chronic heart failure.
Br. Heart J. 1987;57:82.

Lipkin DP, Buller NP, Frenneaux M, Ludgate L, Lowe T, Webb SC,
Krikler DM.
Exercise Capacity and Symptoms are improved by an activity sensing pacemaker ("Activitrax").
Br. Heart J. 1987;57:87.

Buller NP, Jones D, Poole-Wilson PA.
The Mechanism of Fatigue in Chronic Heart Failure.
Br. Heart J. 1988;59:42.

Buller NP, Jones D, Poole-Wilson PA.
Evidence for an intrinsic defect of skeletal muscle metabolism in patients with chronic heart failure.
Clin Sc. 1987;72:60P.

Cripps TR, Buller NP, Rickards AF.
Intracoronary stents for angioplasty of stenoses of saphenous vein aortocoronary bypass grafts.
Br. Heart J. 1990;64:p62.

Buller NP, Pearson MW, Bowker T, Rickards AF.
Absence of coronary artery spasm induced by ergonovine following laser balloon angioplasty.
Eur. Heart J. 1989;10 Abstract Supplement p.

Stewart JT, Williams MG, Mulcahy D, Denne L, Buller NP, Sigwart U, Rickards AF.
Angioplasty of chronic occlusions: risks and benefits.
Circulation 1991;84(Suppl II):333.

Stewart JT, Williams MG, Mulcahy D, Denne L, Buller NP, Sigwart U, Rickards AF.
Disobliteration of occluded right coronary arteries: High risk, low gain.
Eur. Heart J. 1991;12(Suppl):397.

Hacket D. on behalf of the B.E.S.T. investigator group.

Gibbs S, Gunnes P, Blake J, Stewart J, Williams M, Denne L, Buller NP, Sigwart U.
Clinical evaluation of collagen plugs: Single institution experiance after coronary angioplasty and diagnostic angiography.
J. Am. Coll. Cardiol. 1992;19:712A.

Stewart JT, Williams M, Goy J-J, Denne L, Buller NP, Rickards A, Sigwart U.
Stenotic Disease of Saphenous Vein Grafts Treated by Self-expanding Stents.
J. Am. Coll. Cardiol. 1992;19:49A.

Karch K. on behalf of the European Study Group.
The European multicenter registry on coronary excimer laser angioplasty: The first year experience.
J. Am. Coll. Cardiol. 1992;19:48A

Nordrehaug JE, Chronos N, Gunnes P, Rickards AF, Buller NP, Sigwart U.
Safety efficacy and patient tolerability of a new inflatable femoral artery compression device after cardiac angiography.
Br. Heart J. 1992;68:p82
.
Gibbs JSR, Nordrehaug JE, Lin Denne, Simpson IA, Buller NP, Rickards AF, Sigwart U.
Collagen plug for femoral arterial haemostasis after cardiac catheterisation.
Br. Heart J. 1992;68:p82

Chronos N, Mookerjee R, Buller NP, Alison Goodall.
Whole blood flow cytometry: a method for analysing platelet activation in cardiovascular disease.
Br. Heart J. 1992;68:p100.

Chronos N, Mookerjee R, Alison Goodall, Sigwart U, Rickards AF, Buller NP.
Platelet activation: an important side effect of contrast media of relevance to coronary angiography and intervention.
Br. Heart J. 1992;68:p80.

Stewart JT, Williams M, Goy JJ, Denne L, Buller NP, Rickards AF, Sigwart U.
Self-expanding stents for diseased saphenous vein coronary artery bypass grafts.
Br. Heart J. 1992:68:p153.

Gibbs JSR, Simpson IA, Nordrehaug JE, Sigwart U, Rickards AF, Buller NP.
Temporary stenting as a bail-out procedure during coronary angioplasty.
Br. Heart J. 1992:68:p153

Nordrehaug JE, Chronos N, Denne L, Rickards AF, Buller NP, Sigwart U.
Results of stent implantation for the management of aorto ostial stenosis.
Br. Heart J. 1992;68:p154.

Chronos N, Alison Goodall, Sigwart U, Rickards AF, Buller NP.
Assessment of intracoronary platelet activation using a novel sampling technique.
Euro Heart J. 1992;13:Abstract Supplement p1437.

Chronos N, Wilson DJ, Alison Goodall, Sigwart U, Buller NP.
The effect of Aspirin on the expression of neoantigens on the platelet surface membrane in response to physiological agonists.
Euro Heart J. 1992;13:Abstract Supplement p1611.

Gibbs JSR, Slade A, Nordrehaug JE, Blake J, Denne L, Rickards AF, Buller N, Sigwart U.
The use of a collagen plug for femoral artery haemostasis following cardiac catheterisation: single institution experience.
Euro Heart J. 1992;13 Abstract Supplement p2450.

Chronos N, Rickards AF, Sigwart U, Goodall AH, Buller NP.
Contrast media induced platelet activation, an important factor in thrombosis and restenosis following angioplasty
Circulation 1992;86(Suppl I):p445.

Nordrehaug JE, Chronos NA, Foran J, Wainwright R, Rickards AF, Buller NP, Sigwart U.
Randomised evaluation of a new inflatable femoral artery compression device after coronary angiography.
Circulation 1992;86(Suppl I)p382.

Chronos N, Sigwart U, Goodall AH, Buller NP.
Contrast media induced platelet degranulation is dose dependant.
J Am Coll Cardiol. 1993;21:99A.

Chronos N, Wilson DJ, Alison Goodall, Sigwart U, Buller NP.
The effect of Asprin on the expression of neoantigens on the platelet surface membrane in response to physiological agonists.
J Am Coll Cardiol. 1993;21:361A.

Nordrehaug JE, Priestley KA, Chronos NAF, Rickards AF, Buller NP,
Sigwart U.
Self expanding stents for emergency treatment of abrupt closure following PTCA: immediate and long-term results.
Br. Heart J. 1993;69:p20.

Priestley KA, Gibbs JSR, Denne L, Chronos NAF, Rickards AF, Buller NP,
Sigwart U.
Clinical experience with the Palmaz-Schatz stent.
Br. Heart J. 1993;69:p20.

Gibbs JSR, Sigwart U, Buller NP.
International multicentre clinical evaluation of the RX flow support catheter.
Br. Heart J. 1993;69:p21.

Chronos NAF, Wilson DJ, Rickards AF, Sigwart U, Goodall AH, Buller NP.
Contrast media induced platelet degranulation in patients undergoing PTCA.
Br. Heart J. 1993;69:p48.

Priestley KA, Buller NP.
Why so few coronary revascularisation procedures in the UK?
Br. Heart J. 1993;69:p55.

Chronos NAF, Wilson DJ, Buller NP, Goodall AH.
Ionic low osmolar angiographic contrast medium (Hexabrix) has an
anti-thrombin effect, independant of the thrombin receptor.
Thromb Haemost. 1993;69(6):1148(Abstract).

Chronos NAF, Wilson DJ, Gibbs JSR, Sigwart U, Buller NP, Goodall AH.
Heparin and aspirin fail to abolish platelet activation in patients undergoing PTCA.
Thromb Haemost. 1993;69(6):658(Abstract).

Chronos NAF, Wilson DJ, Janes SL, Buller NP, Goodall AH.
Aspirin fails to prevent platelet activation in response to physiological agonists.
Thromb Haemost. 1993;69(6):634(Abstract).

Chronos NAF, Wilson DJ, Buller NP, Goodall AH.
Platelet activation and platelet hyper-responsiveness in patients with stable angina pectoris.
Thromb Haemost. 1993;69(6):967(Abstract).

Chronos NAF, Wilson DJ, Rickards AF, Sigwart U, Goodall AH, Buller NP.
Platelet degranulation and secretion caused by some types of contrast media used for PTCA.
Thromb Haemost. 1993;69(6):1013(Abstract).

Gibbs S,Redington A, Rigby M, Buller N, Sigwart U, Romero L, Shinohara T, Prada F, Somerville J.
Interventional catheterisation in grown-up congenital heart disease.
Euro Heart J. 1993;14 Abstract Supplement p346.

Chronos NAF, Wilson DJ, Gibbs JSR, Goodall AH, Sigwart U, Buller NP.
Heparin and aspirin fail to abolish platelet activation in patients undergoing PTCA.
Euro Heart J. 1993;14 Abstract Supplement p181.

Chronos NAF, Wilson DJ, Goodall AH, Sigwart U, Buller NP.
A new method for the direct measurement of intracoronary platelet activation during PTCA.
Euro Heart J. 1993;14 Abstract Supplement p227.

Chronos NAF, Wilson DJ, Goodall AH, Buller NP.
Platelet activation and platelet hyper-responsiveness in stable angina.
Euro Heart J. 1993;14 Abstract Supplement p412.

Priestley KA, Buller NP.
The effect of a primary health care system on the incidence of coronary revascularisation procedures.
Circulation 1993; 88: Abstract Supplement pI-145.

Karwatowski SP, Forbat SM, Mohiaddin R, Chronos N, Yang GZ, Firmin DN, Buller NP, Underwood R, Longmore DB.
Regional left ventricular long axis function during dobutamine stress in controls and patients with ischaemic heart disease pre and post angioplasty
Circulation 1993; 88: Abstract Supplement pI-83.

Serruys P, Macaya C, de Jaegere P, Kiemeneij F, Rusch W, Heyndrickx G, Emanuelsoson H, Marco J, Legrand V, Marterne P, Belardi J, Buller N, Colombo A, Goy J-J, Delcan J, Morel MA on behalf of the Benestent study group.
Interim Analysis of the Benestent-Trial.
Circulation 1993; 88: Abstract Supplement pI-594.

Sigwart U, Haber RH, Kowlachuk GJ, Simonton CA, Buller NP, Virmani R.
The new ACS metallic Stent: Experimental and clinical experience
Circulation 1993; 88: Abstract Supplement pI-646.

Chronos NA, Patel DJ, Wilson DJ, Goodall AH, Sigwart U, Fox K, Buller NP.
Platelet degranulation by non-ionic contrast media in unstable angina patients.
J Am Coll Cardiol. 1994; Abstract supplement 451A.

Karwatowski SP, Chronos NA, Forbat SM, Mohiaddin R, Yang GZ, Firmin DN, Buller NP, Underwood R, Longmore DB.
Impaired regional left ventricular long axisfunction during dobutamine stress in patients with ischaemic heart disease pre and post angioplasty.
J Am Coll Cardiol. 1994; Abstract supplement 90A.

Stables RH, Chronos NAF, Buller NP.
A graphical user interface database for the results of cardiac catheterisation.
J Am Coll Cardiol. 1994; Abstract supplement 335A.

Karwatowski SP, Chronos NA, Forbat SM, Mohiaddin R, Yang GZ, Firmin DN, Buller NP, Underwood R.
Regional left ventricular function during dobutamine infusion in patients with ischaemic heart disease pre and post angioplasty.
Br. Heart J. 1994;71:p18.

Rickards AF. on behalf of the CABRI investigators.
Coronary angioplasty and coronary surgery in the management of multivessel symptomatic coronary disease: outcomes at 1 year following randomisation in the CABRI trial.
Br. Heart J. 1994;71:p29.

Buller NP, Priestly KA, Sigwart U.
Results of the Benestent study.
Br. Heart J. 1994;71:p30.

Seifalian AM, Stables RH, Arnold S, McNeill J, Chronos N, Buller NP, Hawkes DJ.
Regional coronary bood flow waveforms measured with conventional biplane X-ray angiograms.
Br. Heart J. 1994;71:p83.

Priestley KA, Denne L, Chronos NAF, Sigwart U, Shore D, Buller NP.
Quality of life following coronary revascularisation procedures.
Br. Heart J. 1994;71:p91.

Brady AJB, Rossi AG, Chronos NA, Sigwart U, Buller NP.
Intracoronary activation of polymorphonuclear leucocytes after balloon inflation during PTCA.
Br. Heart J. 1994;71:p94.

Stables RH, Chronos NA, Buller NP.
A graphical user interface database for the results of cardiac catheterisation.
Euro. Heart J.1994;15:(Abstract supplement)p165.

Stables RH, Anagnostopoulos C, Denne B, Underwood R, Buller NP.
Physician prejudice influences treatment allocation in single vessel coronary artery disease: An example of the enthusiasm hypothesis of health care variation.
Br. Heart J. 1995;73:p38.

Stables RH, Gibbs S, Knight C, Groves P, Buller N, Davies SW, Sigwart U.
Post stent management with Femostop and self injected low molecular weight heparin.
Br. Heart J. 1995;73:p88.

Stables RH, Anagnostopoulos C, Denne B, Underwood R, Buller NP.
Physician prejudice influences treatment allocation in single vessel coronary artery disease: An example of the enthusiasm hypothesis of health care variation?
Euro. Heart J.1995;16:(Abstract supplement)p142.

Stables RH, Seifalian AM, McNeill JG, Arnold S, Buller NP, Hawkes DJ.
The measurement of human coronary blood flow with conventional biplane X-ray angiograms.
Euro. Heart J.1995;16:(Abstract supplement)p295.

Stables RH, McNeill JG, Seifaillan AM, Beale CM, Collins PD, Buller NP.
The effect of motion during the cardiac cycle on the accuracy of blood flow velocity estimation by intracoronary doppler probe.
Euro. Heart J.1995;16:(Abstract supplement)p387.

Eccleshall S, Jordan P, Townend J, Buller N.
Lesion moulding catheterisation in the assessment of stent deployment.
Heart. 1997: 77: 21.

Kurbaan AS, Bowker TJ, Rickards AF, on behalf of the CABRI Investigators.
Is repeat revascularisation for restenosis determined by the site of initial angioplasty.
Heart. 1997: 77: 20.

Eccleshall S, Jordan P, Townend J, Buller N.
Assessment of stenosis severity by lesion moulding catheterisation".
Euro. Heart J.1997;18:(Abstract supplement)p616.

Eccleshall SC, Jordan PJ, Townend JN, Buller NP.
The 3-Dimaging catheter in the assessment of stent deployment.
J. Am. Col. Cardiol. 1998; 31 Suppl A 103A.

Eccleshall SC,Jordan PJ, Townend JN, Buller NP.
Measurement of luminal diameter and stenosis severity and assessment of stent deployment using the 3-D imaging catheter.
Proceedings 2nd International Congress on Coronary Artery Disease. 1998.

Eccleshall SC, Buller NP, Townend JN, Claridge E.
A novel method to validate true 3-dimensional imaging of the coronary artery lumen.
Euro. Heart J.1999;20:(Abstract supplement)p309

Hamm C, Doucet S, Hilton D, J te Riele on behalf of the TRUST investigators.
Tenax for the prevention of Restenosis and acute thrombotic complications. A Useful Stent Trial (TRUST). A Clinical Trial.
Euro. Heart J.2001;24:(Abstract supplement).

Doshi SN, Buller NP, Ludman PF, Townend JN.
Acute and medium-term outcomes following the Crush-T stent technique in 21 consecutive bifurcation lesions treated at a single centre.
Heart 2004;90(Suppl 2):56

Doshi SN, Ludman PF, Townend JN, Buller NP.
Estimated annual requirement for drug-eluting stents in a large tertiary referral centre according to recent NICE guidelines.
Heart 2004;90(Suppl 2):138

Doshi SN, Townend JN, Buller NP, Fraser DF, Ludman PF.
Major access related complications following Perclose use compared with manual compression after coronary angioplasty in 1121 consecutive patients.
Euro. Heart J. 2004.

Bowater SE, Doshi SN, Buller NP.
Sub-acute stent thrombosis successfully treated with thrombolysis and glycoprotein IIbIIIa inhibition.
Heart. 2004.

Serruys P, Ong A, Van Herwerden L, Sousa J, Jatene J, Bonnier J, Schonberger J, Buller N, Bonser R, Disco C, Backx B, Hugenholtz P, Firth B, Unger F.
Five year outcomes after coronary stenting verses bypass surgery for the treatment of multivessel disease: the final analysis of the ARTS trial.
Circulation 2004.

Wheatley K, Kalra PA, Moss J, Ives N, Fitzpatrick-Ellis K, Gray R; ASTRAL Collaborative Group.
Lack of benefit of renal artery revascularization in atherosclerotic renovascular disease (ARVD): results of the ASTRAL Trial [Abstract]. Presented at Renal Week 2008, 41st Annual Meeting & Scientific Exposition, Philadelphia, Pennsylvania, 4–9 November 2008. Abstract F-FC206.

Chue CD, Routledge HC, Ludman PF, Townend JN, Epstein ACR, Buller NP, Doshi SN.
3-Year Follow-Up of 100 Consecutive Coronary Bifurcation Lesions Treated with Taxus Stents and the Crush Technique.
Heart 2009-